KLOW Peptit Protokolü: İçerikler, Dozaj ve Araştırma

Summary

The KLOW peptide protocol is a four-peptide blend combining GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg), and TB-500 (10mg) into a single 80mg vial. It builds on the three-peptide GLOW protocol by adding KPV for enhanced anti-inflammatory action.

What You Need to Know

• Four distinct mechanisms in one injection: collagen synthesis (GHK-Cu), NF-kB inhibition (KPV), growth factor modulation (BPC-157), and cell migration (TB-500)
• No clinical trials exist on the KLOW combination itself. All evidence comes from studies on individual components, none of which are FDA-approved
• Standard dosing: 200-500mcg total blend daily via subcutaneous injection, reconstituted with 3-4mL bacteriostatic water
• Typical protocol length: 4-6 weeks on, 2-4 weeks off. The GHK-Cu component carries a copper accumulation risk with prolonged use
• KLOW vs GLOW: the only difference is the addition of KPV. If chronic inflammation or gut issues aren’t part of your picture, GLOW may be sufficient

Use the blend calculator for KLOW dosing | View full KLOW profile

Four Peptides, Four Mechanisms: Why KLOW Exists

The peptide community didn’t invent KLOW out of thin air. It emerged from the observation that the GLOW protocol (GHK-Cu + BPC-157 + TB-500) worked well for tissue repair and skin rejuvenation but left one gap: it didn’t directly address systemic inflammation.

That’s a problem when healing needs to happen alongside an active inflammatory response. Think autoimmune flare-ups, chronic gut inflammation, or recovery from illness where the immune system is still running hot. BPC-157 and TB-500 both have anti-inflammatory properties, sure, but their primary mechanisms target tissue repair pathways. They reduce inflammation as a secondary effect.

KPV is different. It walks straight into the cell nucleus and shuts down NF-kB, the master switch controlling inflammatory cytokine production (Kannengiesser et al., Anti-Inflammatory Mechanisms, 2020). No other peptide in the GLOW stack does that.

What’s Actually in a KLOW Vial

A standard KLOW vial contains 80mg total across four peptides in a fixed 5:1:1:1 ratio.

GHK-Cu dominates the blend at 62.5%. That ratio reflects its naturally lower potency per milligram compared to the other three peptides and the fact that effective GHK-Cu doses (1-3mg daily) are significantly higher than effective BPC-157 doses (250-500mcg daily).

Breaking Down Each Component

GHK-Cu: The Collagen Engine

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a tripeptide naturally present in human plasma. Your body produces it. Levels decline with age: roughly 200 ng/mL at age 20, dropping to about 80 ng/mL by age 60.

What makes GHK-Cu unusual is scope. A 2018 analysis in the International Journal of Molecular Sciences found it affects 31.2% of human genes, modulating everything from collagen production to antioxidant enzyme expression. A separate 2015 study in Biomedical Research International measured a 70% increase in type I and III collagen and improved elastin production in skin tissue treated with GHK-Cu.

The copper ion isn’t decorative. It’s an essential cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin fibres. Without copper, those fibres form but don’t properly connect.

Molecular weight: 404.96 Da | Half-life: 0.5-2 hours | Sequence: Gly-His-Lys-Cu2+

KPV: The Inflammation Kill Switch

KPV is a tripeptide derived from the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It carries alpha-MSH’s anti-inflammatory properties without causing skin darkening. Three amino acids. That’s it.

The mechanism is direct. KPV enters cells and inhibits NF-kB signalling at the nuclear level, reducing production of TNF-alpha and IL-6 (Kannengiesser et al., 2020). A 2021 study on psoriasis models showed 60% reduction in psoriatic inflammatory markers. In IBD models (2019), KPV reduced intestinal inflammation and supported barrier repair.

Critically, KPV doesn’t cause immunosuppression the way corticosteroids do. It modulates inflammation rather than blanket-suppressing immune function. That distinction matters for long-term use.

Half-life: 1-2 hours | Delivery: Injectable, oral, topical, nasal

BPC-157: The Healing Workhorse

BPC-157 has the deepest research base of the four. Over 100 animal studies spanning three decades. It’s a 15-amino-acid synthetic peptide derived from a protein found in human gastric juice, and it works primarily through VEGF-mediated angiogenesis and growth factor expression.

The strength of BPC-157 is breadth. Tendons, muscles, ligaments, gut lining, nerves, blood vessels. A 2017 study demonstrated enhanced VEGF expression and new blood vessel formation at injury sites. A 2020 safety evaluation found no serious adverse effects at 1000mcg/kg for 90 days in animal models.

The weakness is human evidence. Only three published human studies exist as of early 2026, all small pilot studies. A 2024 pilot on interstitial cystitis (12 patients) showed 80-100% symptom resolution. Promising, but far from definitive.

Molecular weight: 1,419.53 Da | Half-life: under 30 minutes | 15 amino acids

TB-500: The Migration Signal

TB-500 is a synthetic fragment of thymosin beta-4, the principal actin-sequestering protein in mammalian cells. It regulates cell migration, which is the process of cells moving toward injury sites.

TB-500 has stronger human data than BPC-157. A 2012 Phase 2 trial in Dermal Wound Healing studied chronic pressure ulcers. A 2016 cardiac trial demonstrated over 50% improvement in left ventricular function post-myocardial infarction. A 2014 Phase 2 trial showed benefit for dry eye (corneal healing).

The longer half-life (approximately 2 hours versus BPC-157’s 30 minutes) means TB-500 distributes systemically. It doesn’t need to be injected near the injury.

Molecular weight: 4,963.44 Da | Half-life: ~2 hours | 43 amino acids